Revance Therapeutics, a clinical stage biotechnology company based in Nashville, develops novel botulinum toxin products, including DAXXIFY and the RHA Collection of dermal fillers. The company partners with Viatris and Fosun for biosimilar development and commercialization in China.
RVNC has been in the news recently: Levi & Korsinsky, LLP, along with other law firms, is filing class action lawsuits for Revance Therapeutics investors who incurred losses between February 29 and December 6, 2024. Investors are encouraged to join these lawsuits before the lead plaintiff deadline of March 4, 2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
